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Every year, a large number of people fall prey to cancer
worldwide and more than half lose their battle to cancer.
Among the multimodalities of cancer management, in-
cluding surgery, hormonal therapy, radiotherapy, and
chemotherapy, immunotherapy has revolutionized the
treatment of cancer. Immune-oncology is a rapidly devel-
oping and exciting field of cancer treatment with the pro-
spective of impacting the management of a wide array of
malignancies which have recently witnessed a steep rise.
!e major goal of cancer immunotherapy is to alleviate
tumor-associated suppression of anticancer immune re-
sponses. !e basic notion of utilizing a patient’s immune
system against cancer cells dates back to 1997, since the
immune system response versus virulent cells during initial
transformation in the immune surveillance process was
discovered. Cancer immunotherapy, which is occasionally
referred to as immune-oncology, induces the patient’s own
immune system and attempts to exploit the exquisite power
and specificity of the immune system for cancer patient
treatment. Immunotherapy against cancers encompasses a
diverse continuum of approaches, ranging from stimulating
effector mechanisms to counteracting inhibitory and sup-
pressive mechanisms. Owing to the swift knowledge
amassed by the scientific community about the immune
system, small molecules, peptides, recombinant antibodies,
vaccines, and cellular therapeutic modalities are being ap-
plied to manipulate the immune response to treat cancer.
With recent success, immunotherapy has emerged as a
pragmatic strategy and a reputable pillar of cancer treatment
improving the prognosis of many patients suffering from
different malignancies. !e two main drivers behind this
success are immune checkpoint inhibitors (CPIs) and chi-
meric antigen receptor- (CAR-) T cells. For checkpoint
blockade, current studies emphasize combinational ap-
proaches, perioperative use, response prediction, new tumor
entities, toxicity management, and use in special patient
populations. Regarding cellular immunotherapy, recent
studies confirmed safety and efficacy of CAR-Tcells in larger
cohorts of patients with acute lymphoblastic leukemia or
diffuse large B-cell lymphoma. Different strategies to
translate the conspicuous triumph of CAR-T cells in B-cell
malignancies to other hematological and solid cancer types
are currently in clinical investigation phase. Since cancer is
still one of the deadly challenges that are faced by humans,
treatment regimes with single-drug therapies are not
yielding very effective results in terms of improving the
patient survival and treatment, and therefore, a combination
of two or more therapies targeting different mechanisms
could be more efficacious.
!e purpose of this special issue is to present the recent
progress in this exciting field. A brief summary of all ac-
cepted papers is provided as follows.
In the review article by M. Sambi et al., the authors have
described the options to improve patient response rate to
immunotherapy with an emphasis on adopting a multi-
modal approach with an emphasis on the novel role that the
gut microbiota may play in modulating the efficacy of cancer
immunotherapy.
!e paper by D. D. Goycoechea et al. provides an ex-
tensive and critical review of the literature regarding
Hindawi
Journal of Oncology
Volume 2020, Article ID 3548603, 2 pages
https://doi.org/10.1155/2020/3548603
immune checkpoint inhibition in classical Hodgkin lym-
phoma. !e paper discusses the early achievements and pro-
vides new perspectives on immune checkpoint inhibition in a
disease that constitutes a model of sensitivity to this treatment.
!e paper by A. Rogiers et al. presents an updated and
comprehensive review of the results of themain clinical trials
in the field of immunotherapy in melanoma and highlights
potential consequences on the psychosocial wellbeing,
neurocognitive functions, and life quality of patients.
In the research article by P. Darvin et al., the authors
investigated the regulation of PD-L1 expression in breast
cancer tumor spheres compared to cell lines. !ey show that
PD-L1 is likely regulated by histone modifications rather
than DNA methylation.
In the paper by D. Wu et al., the authors reached the
conclusion that CTP is currently the most effective neo-
adjuvant regimen for the chance of achieving pathological
complete response (pCR), with little additional toxicity com-
pared, and MP has the best tolerability and acceptable efficacy.
In the research article by A. Rossi et al., the authors point
out that ALDH levels are elevated in the serum of NSCLC
patients with advanced stage as well as in early stage disease
and therefore can be evaluated as part of the panel of
markers for noninvasive detection of early NSCLC in a
larger cohort of patients at risk.
In the paper by A. C. Mart´ınez-Torres et al., the authors
have discovered that PKHB1, a TSP1-derived CD47 agonist
peptide, can induce immunogenic cell death in tumoral T
lymphoblasts. Tumor cell lysate (TCL) from PKHB1-treated
lymphoblasts can induce DC maturation and T-cell acti-
vation ex vivo. Also, TCL can be used as tumor vaccine,
when administrated in either prophylactic or therapeutic
settings.
In the review article by C. Fiorentini et al., the authors
have reviewed clinical results of immunotherapy in ACC
and highlighted molecular mechanisms that lead to im-
munotherapy failure in ACC. !ey have also suggested
possible approaches to prevail over resistance.
In the review article by R. E. Cooke et al., the authors
have discussed the concept of immune profiling to target
patients of multiple myeloma who might benefit the most
from immunotherapeutics. !e review also covers the ad-
vances and use of humanized mice as well as 3D culture
systems for personalized medicine.
In the paper by M. Kreidieh et al., the authors have
reviewed in detail about treatment strategy in liver cancer
including radiation therapy and immunotherapy alone and
in combination. !e study also explores the evidence sur-
rounding the use of SBRT and immunotherapy for the
treatment of HCC and CCA.
In the paper by F. Toia et al., the authors have presented a
systematic review of preclinical and clinical studies on cδ
T cell-based immunotherapy and melanoma, in which the
discussion is mainly focused on research state of the art and
future perspectives.
In the review article by F. Ghali et al., the authors have
reviewed the current status of adjuvant and neoadjuvant
immunotherapy in localized and locally advanced renal cell
carcinoma, combining discussion of recently published,
ongoing clinical trials and future concepts in this fast
moving area of investigation.
In the paper by M. A. I. Al-Hatamleh et al., the authors
have reviewed the implications of tumour necrosis factor
and its receptor 2 (TNFR2) expressions in breast cancer, the
oncogenic consequences, and their role in the suppressive
immune responses by TRegs. !ey have described the use of
nanoparticles as a targeted drug delivery agent in immu-
notherapy, based on their advantageous properties. !e
review also discusses the manipulation of NPs with TNF-
antagonist to modulate TNF-TNFR2 interaction that in-
hibits breast cancer progression.
In the research article by E.-G. Chavez-Cortez et al., the
authors show a novel, affordable, and effective tumor, glio-
blastoma. !e immunotoxin produced and tested in this in-
vestigation, i.e., IgY-abrin immunotoxin, had cytotoxic activity
against CD133+ malignant glioma stem cells and provided a
novel approach for the immunotherapy of glioblastoma.
!e research article by U. Swami et al. suggests that
advanced melanoma patients discontinuing anti-PD-1
therapy due to irAE usually experience durable clinical benefit.
However, caution is needed with these agents in patients with
underlying autoimmune diseases. !e study explored durable
clinical benefit in this subset of patients. !e manuscript
goes in detail of each immune-toxicity and its management.
!e review by S. P. Singh et al. provides an interesting
overview of the role of cancer stem cells and molecular
pathways that are aberrantly expressed in these cells. !is
review article also provides an updated description of
markers expressed by cancer stem cells and used for their
isolation. It also covers the options of treatment of cancer
stem cells with immunotherapy. !erefore, examples of
molecules/pathways expressed by cancer stem cells that
could represent target for immunotherapy approaches are
also included in the review.
Conflicts of Interest
!e editors declare that they have no conflicts of interest
regarding the publication of this Special Issue.
Acknowledgments
We would like to express our gratitude to all the authors and
reviewers who made this special issue possible. We would
like to thank one of our guest editors Dr. Kishore B.
Challangundla from the Dept of Biochemistry & Molecular
Biology at the University of Nebraska Medical Center, USA.
We would like to specially thank Dr. Saurabh Pratap Singh
from my research team from the Department of Oral Pa-
thology & Microbiology, King George’s Medical University,
India, for helping in the process of screening articles and
deciding reviewers for the articles. We hope this collection of
articles will be useful to the scientific community.
Shalini Gupta
Subash C. Gupta
Keith D. Hunter
Aditya B. Pant
2 Journal of Oncology
